russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2025-6457FCITGYrussjcardiol-6457Research ArticleЛЕГОЧНАЯ ГИПЕРТЕНЗИЯЛегочная гипертензия у пациентов с сердечной недостаточностью с сохраненной фракцией выброса (обзор литературы)Pulmonary hypertension in patients with heart failure with preserved ejection fraction: a literature reviewhttps://orcid.org/0000-0003-3002-1067ЯфароваА. А.YafarovaA. A.

Яфарова Адель Айратовна — врач-кардиолог, к.м.н., м.н.с. лаборатории по изучению кишечной микробиоты человека.

Петроверигский пер., д. 10, стр. 3, Москва, 101990

Petroverigsky Lane, 10, bld. 3, Moscow, 101990

yafarova-adel@rambler.ruhttps://orcid.org/0009-0000-0208-9545ФилипповК. Г.FilippovK. G.

Филиппов Константин Георгиевич — врач-кардиолог, аспирант по специальности "Кардиология".

Петроверигский пер., д. 10, стр. 3, Москва, 101990

Petroverigsky Lane, 10, bld. 3, Moscow, 101990

philippovkg11@gmail.comhttps://orcid.org/0000-0002-5384-3795ДжиоеваО. Н.DzhioevaO. N.

Джиоева Ольга Николаевна — д.м.н., в.н.с., руководитель лаборатории кардиовизуализации, вегетативной регуляции и сомнологии.

Петроверигский пер., д. 10, стр. 3, Москва, 101990

Petroverigsky Lane, 10, bld. 3, Moscow, 101990

ODzhioeva@gnicpm.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Михайловна — д.м.н., профессор, академик РАН, директор.

Петроверигский пер., д. 10, стр. 3, Москва, 101990

Petroverigsky Lane, 10, bld. 3, Moscow, 101990

drapkina@bk.ruФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава РоссииРоссияNational Medical Research Center for Therapy and Preventive MedicineRussian Federation202526012026302SОбразование64576457Copyright © Яфарова А.А., Филиппов К.Г., Джиоева О.Н., Драпкина О.М., 20262026Яфарова А.А., Филиппов К.Г., Джиоева О.Н., Драпкина О.М.Yafarova A.A., Filippov K.G., Dzhioeva O.N., Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/6457

Легочная гипертензия (ЛГ), развивающаяся на фоне сердечной недостаточности с сохранённой фракцией выброса (СНсФВ), является распространённым и прогностически неблагоприятным состоянием. В обзоре рассматриваются эпидемиология, патогенез, подтипы ЛГ, а также ключевые биомаркеры и гемодинамические показатели, влияющие на прогноз. Особое внимание уделено роли правожелудочковой дисфункции и сосудистого ремоделирования при комбинированной ЛГ. Представлены диагностические алгоритмы, отражающие сложности дифференциальной диагностики между легочной артериальной гипертензией и ЛГ-СНсФВ. Обзор подчёркивает важность раннего выявления и персонифицированного подхода к пациентам с ЛГ-СНсФВ.

Pulmonary hypertension (PH) in the context of heart failure with preserved ejection fraction (HFpEF) is a prevalent and prognostically adverse condition. This review examines the epidemiology, pathogenesis, and subtypes of PH, as well as key biomarkers and hemodynamic parameters that influence prognosis. Key biomarkers and diagnostic thresholds are discussed alongside recent classification updates. The review emphasizes diagnostic challenges, especially distinguishing PH-HFpEF from pulmonary arterial hypertension. The review emphasizes the importance of early identification and a personalized approach to patients with PH-HFpEF.

легочная гипертензиясердечная недостаточность с сохранённой фракцией выбросапрогнозстратификация рискаpulmonary hypertensionheart failure with preserved ejection fractionprognosisrisk stratificationReferencesАвдеев С. Н., Барбараш О. Л., Валиева З. С. и др. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6161. doi:10.15829/1560-4071-2024-6161.Avdeev SN, Barbarash OL, Valieva ZS, et al. 2024 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2024;29(11):6161. (In Russ.) doi:10.15829/1560-4071-2024-6161.Rosenkranz S, Gibbs JSR, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37:942-54. doi:10.1093/eurheartj/ehv512.Rosenkranz S, Gibbs JSR, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37:942-54. doi:10.1093/eurheartj/ehv512.Humbert M, Galiè N, Rubin LJ, et al. The Seventh World Symposium on Pulmonary Hyper­tension: our journey to Barcelona. Eur Respir J. 2024;64(4):2401222. doi:10.1183/13993003.01222-2024.Humbert M, Galiè N, Rubin LJ, et al. The Seventh World Symposium on Pulmonary Hyper­tension: our journey to Barcelona. Eur Respir J. 2024;64(4):2401222. doi:10.1183/13993003.01222-2024.Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. doi:10.1183/13993003.00879-2022.Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. doi:10.1183/13993003.00879-2022.Borlaug BA, Larive B, Frantz RP, et al. Pulmonary hypertension across the spectrum of left heart and lung disease. Eur J Heart Fail. 2024;26:1642-51. doi:10.1002/ejhf.3302.Borlaug BA, Larive B, Frantz RP, et al. Pulmonary hypertension across the spectrum of left heart and lung disease. Eur J Heart Fail. 2024;26:1642-51. doi:10.1002/ejhf.3302.Madonna R, Biondi F, Ghelardoni S, et al. Pulmonary hypertension associated to left heart disease: phenotypes and treatment. Eur J Intern Med. 2024;129:1-15. doi:10.1016/j.ejim.2024.07.030.Madonna R, Biondi F, Ghelardoni S, et al. Pulmonary hypertension associated to left heart disease: phenotypes and treatment. Eur J Intern Med. 2024;129:1-15. doi:10.1016/j.ejim.2024.07.030.Vanderpool RR, Saul M, Nouraie M, et al. Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol. 2018;3:298-306. doi:10.1001/jamacardio.2018.0128.Vanderpool RR, Saul M, Nouraie M, et al. Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol. 2018;3:298-306. doi:10.1001/jamacardio.2018.0128.Поляков Д. С., Фомин И. В., Беленков Ю. Н. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА -ХСН. Кардиология. 2021;61(4):4-14. doi:10.18087/cardio.2021.4.n1628.Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.) doi:10.18087/cardio.2021.4.n1628.Агеев Ф. Т., Овчинников О. Г. Диастолическая сердечная недостаточность: 20 лет спустя. Актуальные вопросы патогенеза, диагностики и лечения хронической сердечной недостаточности с сохраненной ФВ ЛЖ. Кардиология. 2023;63(3):3-12. doi:10.18087/cardio.2023.3.n2376.Ageev FT, Ovchinnikov AG. Diastolic heart failure: 20 years later. Сurrent issues of pathoge­nesis, diagnosis and treatment of heart failure with preserved LVEF. Kardiologiia. 2023;63(3):3-12. (In Russ.) doi:10.18087/cardio.2023.3.n2376.Butrous G. Pulmonary hypertension aetiologies in different parts of the world. Int J Cardiol Congenit Heart Dis. 2025;20:100586. doi:10.1016/j.ijcchd.2025.100586.Butrous G. Pulmonary hypertension aetiologies in different parts of the world. Int J Cardiol Congenit Heart Dis. 2025;20:100586. doi:10.1016/j.ijcchd.2025.100586.Tromp J, Teng TH, Tay WT, et al.; ASIAN-HF Investigators. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019;21(1):23-36. doi:10.1002/ejhf.1227.Tromp J, Teng TH, Tay WT, et al.; ASIAN-HF Investigators. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019;21(1):23-36. doi:10.1002/ejhf.1227.Inampudi C, Silverman D, Simon MA, et al. Pulmonary hypertension in the context of heart failure with preserved ejection fraction. Chest. 2021;160:2232-46. doi:10.1016/j.chest.2021.08.039.Inampudi C, Silverman D, Simon MA, et al. Pulmonary hypertension in the context of heart failure with preserved ejection fraction. Chest. 2021;160:2232-46. doi:10.1016/j.chest.2021.08.039.Khan M, Suribhatla R, Spencer J, et al. Investigating the prevalence of pulmonary hypertension amongst individuals with heart failure: a systematic review and meta-analysis. Thorax. 2023;78. doi:10.1136/thorax-2023-BTSabstracts.296.Khan M, Suribhatla R, Spencer J, et al. Investigating the prevalence of pulmonary hypertension amongst individuals with heart failure: a systematic review and meta-analysis. Thorax. 2023;78. doi:10.1136/thorax-2023-BTSabstracts.296.Damy T, Goode KM, Kallvikbacka-­Bennett A, et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J. 2010;31:2280-90.Damy T, Goode KM, Kallvikbacka-­Bennett A, et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J. 2010;31:2280-90.Guazzi M, Ghio S, Adir Y. Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week. J Am Coll Cardiol. 2020;76:1102-11. doi:10.1016/j.jacc.2020.06.069.Guazzi M, Ghio S, Adir Y. Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week. J Am Coll Cardiol. 2020;76:1102-11. doi:10.1016/j.jacc.2020.06.069.Salamon JN, Kelesidis I, Msaouel P, et al. Outcomes in World Health Organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-­induced pulmonary hypertension. J Card Fail. 2014;20:467-75. doi:10.1016/j.cardfail.2014.05.003.Salamon JN, Kelesidis I, Msaouel P, et al. Outcomes in World Health Organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-­induced pulmonary hypertension. J Card Fail. 2014;20:467-75. doi:10.1016/j.cardfail.2014.05.003.Hussain N, Charalampopoulos A, Ramjug S, et al. Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management. Pulm Circ. 2016;6(1):3-14. doi:10.1086/685021.Hussain N, Charalampopoulos A, Ramjug S, et al. Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management. Pulm Circ. 2016;6(1):3-14. doi:10.1086/685021.Allen BJ, Frye H, Ramanathan R, et al. Biomechanical and mechanobiological drivers of the transition from postcapillary pulmonary hypertension to combined pre-/postcapillary pulmonary hypertension. J Am Heart Assoc. 2023;12: e028121. doi:10.1161/JAHA.122.028121.Allen BJ, Frye H, Ramanathan R, et al. Biomechanical and mechanobiological drivers of the transition from postcapillary pulmonary hypertension to combined pre-/postcapillary pulmonary hypertension. J Am Heart Assoc. 2023;12: e028121. doi:10.1161/JAHA.122.028121.Fayyaz AU, Edwards WD, Maleszewski JJ, et al. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation. 2018;137:1796-810. doi:10.1161/CIRCULATIONAHA.117.031608.Fayyaz AU, Edwards WD, Maleszewski JJ, et al. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation. 2018;137:1796-810. doi:10.1161/CIRCULATIONAHA.117.031608.Галявич А. С., Терещенко С. Н., Ускач Т. М. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162. doi:10.15829/1560-4071-2024-6162.Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.) doi:10.15829/1560-4071-2024-6162.Gorter TM, van Veldhuisen DJ, Voors AA, et al. Right ventricular-­vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. Eur Heart J Cardiovasc Imaging. 2018;19(4):425-32. doi:10.1093/ehjci/jex133.Gorter TM, van Veldhuisen DJ, Voors AA, et al. Right ventricular-­vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. Eur Heart J Cardiovasc Imaging. 2018;19(4):425-32. doi:10.1093/ehjci/jex133.Opitz CF, Hoeper MM, Gibbs JS, et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol. 2016;68(4):368-78.Opitz CF, Hoeper MM, Gibbs JS, et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol. 2016;68(4):368-78.Guazzi M. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. Circ Heart Fail. 2014;7(2):367-77. doi:10.1161/CIRCHEARTFAILURE.113.000823.Guazzi M. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. Circ Heart Fail. 2014;7(2):367-77. doi:10.1161/CIRCHEARTFAILURE.113.000823.Assad TR, Hemnes AR, Larkin EK, et al. Clinical and Biological Insights Into Combined Post- and Pre-­Capillary Pulmonary Hypertension. J Am Coll Cardiol. 2016;68(23):2525-36. doi:10.1016/j.jacc.2016.09.942.Assad TR, Hemnes AR, Larkin EK, et al. Clinical and Biological Insights Into Combined Post- and Pre-­Capillary Pulmonary Hypertension. J Am Coll Cardiol. 2016;68(23):2525-36. doi:10.1016/j.jacc.2016.09.942.Omote K, Sorimachi H, Obokata M, et al. Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. Eur Heart J. 2022;43(36):3417-31. doi:10.1093/eurheartj/ehac184.Omote K, Sorimachi H, Obokata M, et al. Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. Eur Heart J. 2022;43(36):3417-31. doi:10.1093/eurheartj/ehac184.Damy T, Kallvikbacka-­Bennett A, Goode K, et al. Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure. J Card Fail. 2012;18:216-25. doi:10.1016/j.cardfail.2011.12.003.Damy T, Kallvikbacka-­Bennett A, Goode K, et al. Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure. J Card Fail. 2012;18:216-25. doi:10.1016/j.cardfail.2011.12.003.Mohammed SF, Borlaug BA, Roger VL, et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-­based study. Circ Heart Fail. 2012;5:710-19. doi:10.1161/CIRCHEARTFAILURE.112.968594.Mohammed SF, Borlaug BA, Roger VL, et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-­based study. Circ Heart Fail. 2012;5:710-19. doi:10.1161/CIRCHEARTFAILURE.112.968594.Burke MA, Katz DH, Beussink L, et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7(2):288-99. doi:10.1161/CIRCHEARTFAILURE.113.000854.Burke MA, Katz DH, Beussink L, et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7(2):288-99. doi:10.1161/CIRCHEARTFAILURE.113.000854.

The authors declare that there are no conflicts of interest present.